Foundayo FDA Approval and Launch Outlook for Q1 2026

Early indicators of FDA approval and Q1 2026 launch prospects for Foundayo

1) FDA approval status and what it implies for “approval prospects”

• Eli Lilly stated that orforgopron was approved by the U.S. FDA under the trade name Foundayo in the “Earlier this month” timeframe of the Q1 2026 call/period referenced in the transcript. ¹
• Management characterized the approval as the “important first step” for commercialization and noted that the company is encouraged by momentum against its 2026 launch priorities even though the Foundayo launch had “just begun.” ¹

Bottom line: Based on the excerpt, FDA approval is already achieved for the U.S. obesity indication by Q1 2026, so “FDA approval prospects” are no longer a forward-looking question in Q1—they transition into execution and access ramp. ¹

---

2) Q1 2026 launch momentum: early commercial/sales execution indicators

Management described the early launch trajectory as encouraging, supported by three execution “catalysts” (HCP familiarity, access/awareness, and consumer adoption). ²

A. Health-care provider (HCP) adoption indicators

• Lilly reported over 8,000 prescribers of Foundayo, with 1/3 of them not previously written an oral GLP-1, which management framed as “expansive” new-to-class reach. ²
• Lilly said it was “fully in the field” with promotional offers and continuing execution including sampling, promotions, and educational seminars. ²

B. Access indicators (commercial + Medicare pathway)

• Lilly stated it confirmed commercial access at 2 of the large PBMs by middle of May (described as “just in a couple of weeks” in the call context). ²
• For Medicare access, management said it will start at the beginning of July via the bridge program. ²
• Separately, Lilly also stated that the GLP-1 bridge program will start no later than July 1, reinforcing the timing of Medicare/insurance expansion. ³

These timing points are important for Q1 “prospects” because they suggest that part of the access ramp is still ahead of Q1, especially Medicare, which could be a later 2026 growth unlock beyond initial Q1 activity. ²³

C. Consumer/patient adoption indicators

• Lilly reported just over 20,000 patients treated to date, and stated that 80% of those prescriptions were for patients new to class. ²
• In another part of the transcript, management referenced early launch patient starts, including commentary about 15,000 patients starting therapy “already” within “a few weeks of launch under your belt.” ⁴

Bottom line: Within the Q1 2026 launch window described, the company’s early indicators show rapid initial prescriber penetration, meaningful “new to class” uptake, and improving access that continues to roll out through PBMs and Medicare later in 2026. ²⁴

---

3) “Launch channel availability” signals relevant to Q1 2026 prospects

• Lilly indicated that Foundayo became broadly available in pharmacies on April 9 and is available on more than 12 major telehealth platforms. ⁵
• Management also described accelerated primary-care DTC activation, stating that from day one it activated a set of digital, social media, and out-of-home advertising in the first week after approval. ⁶
• Lilly said full-scale direct-to-consumer TV launch is planned for Q3, but acknowledged discipline around ensuring prescriber understanding before scaling fully. ⁷⁶

Implication for Q1 2026 prospects: Q1’s prospects appear driven more by HCP education and early market familiarity than a full national TV push (scheduled for Q3), while patient starts and prescriber counts suggest early traction is already forming. ²⁷⁶

---

4) Early “leading indicators” management cited as predictors of build-over-time growth

Lilly explicitly framed the early phase as:

• “early days” but “pretty pleased with the trajectory” and “encouraging first start to launch.” ²
• They cited three key growth factors:
  1. familiarity among health care providers on the clinical profile, ²
  2. building access and awareness with consumers, ²
  3. progress on access expansion, including PBMs and Medicare via the bridge program (with timing referenced for commercial and Medicare). ²

They also characterized the near-term trajectory as expected to build over time. ⁷

---

5) Clinical/regulatory credibility underpinning commercialization prospects (context for FDA approval)

While launch prospects are commercial, Lilly also anchored demand expectations in the FDA-approved clinical framing:

• Foundayo was described as proven highly effective for weight management and as enabling GLP-1 benefits in a pill form with no food or water restrictions. ¹
• Lilly called Foundayo a new molecule/new modality and noted it was the first time a new incretin medicine has been launched with obesity as its indication first (as stated in the transcript). ¹

This is relevant because regulators’ approval tends to be the starting gate; management’s messaging suggests the company expects demand to grow as clinicians and consumers become comfortable with the profile differences (oral, timing flexibility, and restrictions). ¹²

---

Overall conclusion (Q1 2026)

• FDA approval: Achieved in the U.S. (orforgopron approved as Foundayo) by the Q1 2026 period referenced. ¹
• Early launch prospects in Q1 2026: The company reports positive early leading indicators—notably 8,000+ prescribers, 20,000+ treated patients, and 80% new-to-class prescriptions, alongside expanding commercial access (PBMs) and an upcoming Medicare unlock in early July/July 1. ²⁴³
• What remains ahead: Medicare/Part D bridge access timing and full-scale consumer TV in Q3 indicate Q1’s traction is only part of a longer ramp; management is deliberately sequencing channel activation and HCP familiarity before broader consumer scaling. ²⁷⁶

All conclusions above are grounded strictly in the cited excerpts and reflect the early indicators management shared during the Q1 2026 call/period. ^2174653